Insights on CXC chemokine receptor 2 in breast cancer: An emerging target for oncotherapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer remains a leading cause of cancer-related deaths in women globally, with existing treatments often suboptimal.
• Molecular typing guides targeted therapy, and CXC chemokine receptor 2 (CXCR2) is identified as a key marker.
• CXCR2, a G-protein-coupled receptor, and its ligands are increasingly linked to various tumor-promoting processes.

Purpose of the Study:

• To review the biological functions and mechanisms of CXC chemokine receptor 2 (CXCR2) and its ligands.
• To elucidate the role of CXCR2 in breast cancer development and progression.
• To explore the potential of targeting CXCR2 as a therapeutic strategy for breast cancer.

Main Methods:

• Literature review focusing on structural and mechanistic aspects of CXCR2 and its ligands.
• Analysis of studies investigating the involvement of CXCR2 in breast cancer pathogenesis.
• Evaluation of preclinical and clinical data on CXCR2 inhibition in breast cancer models.

Main Results:

• CXCR2 signaling is implicated in critical tumor-associated processes including proliferation, angiogenesis, invasion, metastasis, and chemoresistance.
• CXCR2 plays a role in maintaining cancer stem cell populations and their stemness.
• Inhibition of CXCR2 or its downstream pathways demonstrates potential to impede tumor progression.

Conclusions:

• CXC chemokine receptor 2 (CXCR2) is a significant factor in breast cancer development and progression.
• Targeting CXCR2 presents a promising therapeutic avenue to improve breast cancer treatment outcomes.
• Further research into CXCR2 inhibition could supplement existing clinical strategies and enhance patient prognosis.